Previous Close | 47.84 |
Open | 46.60 |
Bid | 40.87 x 200 |
Ask | 44.29 x 100 |
Day's Range | 38.22 - 46.85 |
52 Week Range | 19.83 - 94.75 |
Volume | |
Avg. Volume | 1,315,214 |
Market Cap | 5.339B |
Beta (5Y Monthly) | 0.89 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mark Delong, Chief Business & Strategy Officer of Apellis Pharmaceuticals Inc (NASDAQ:APLS), has sold 9,913 shares of the company on March 18, 2024, according to a recent SEC filing.
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]